Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hallqvist

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Oncoimmunology|February 12, 2024
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancerPatrik Sundström, Nikita Dutta, William Rodin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 13, 2017
Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: A systematic review and meta-analysisAndreas Hallqvist, Charlotte Alverbratt, Annika Strandell, et al.
Biomedicines|November 27, 2021
Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry RationaleAndreas Hallqvist, Johanna Svensson, Linn Hagmarker, et al.
Critical Reviews in Oncology/Hematology|May 16, 2018
Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysisPer Albertsson, Charlotte Alverbratt, Ann Liljegren, et al.
Frontiers in Oncology|June 17, 2024
Assessing the prognostic value of <i>KRAS</i> mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysisElla A Eklund, Ali Mourad, Clotilde Wiel, et al.
Radiation Oncology (London, England)|December 17, 2024
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trialsAstrid E Persson, Andreas Hallqvist, Louise Bjørn Larsen, et al.
Translational Oncology|September 28, 2020
Evaluation of therapeutic efficacy of <sup>211</sup>At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancerStig Palm, Tom Bäck, Emma Aneheim, et al.
Cancers|May 14, 2022
<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung CancerElla A Eklund, Clotilde Wiel, Henrik Fagman, et al.
Frontiers in Medicine|January 23, 2023
Astatine-211 based radionuclide therapy: Current clinical trial landscapePer Albertsson, Tom Bäck, Karin Bergmark, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal RadioimmunotherapyErik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Oncoimmunology|February 12, 2024
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancerPatrik Sundström, Nikita Dutta, William Rodin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 13, 2017
Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: A systematic review and meta-analysisAndreas Hallqvist, Charlotte Alverbratt, Annika Strandell, et al.
Biomedicines|November 27, 2021
Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry RationaleAndreas Hallqvist, Johanna Svensson, Linn Hagmarker, et al.
Critical Reviews in Oncology/Hematology|May 16, 2018
Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysisPer Albertsson, Charlotte Alverbratt, Ann Liljegren, et al.
Frontiers in Oncology|June 17, 2024
Assessing the prognostic value of <i>KRAS</i> mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysisElla A Eklund, Ali Mourad, Clotilde Wiel, et al.
Radiation Oncology (London, England)|December 17, 2024
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trialsAstrid E Persson, Andreas Hallqvist, Louise Bjørn Larsen, et al.
Translational Oncology|September 28, 2020
Evaluation of therapeutic efficacy of <sup>211</sup>At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancerStig Palm, Tom Bäck, Emma Aneheim, et al.
Cancers|May 14, 2022
<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung CancerElla A Eklund, Clotilde Wiel, Henrik Fagman, et al.
Frontiers in Medicine|January 23, 2023
Astatine-211 based radionuclide therapy: Current clinical trial landscapePer Albertsson, Tom Bäck, Karin Bergmark, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal RadioimmunotherapyErik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Pageof 4